# ATB Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atb-therapeutics

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.atbtherapeutics.com/
- Total disclosed funding: $16M
- Latest round: Series A (Oct 29, 2024)
- Investors on record: 7

## About

Based in Belgium and founded by co-founders Bertrand Magy (CEO), Ludwig Camusot, and Max Houry, ATB Therapeutics, Inc. specializes in creating targeted therapies for oncology and autoimmune diseases. In November 2024, ATB Therapeutics, Inc. raised EUR 54 million in Series A funding co-led by EQT Life Sciences and MRL Ventures Fund, with participation from other V-Bio Ventures, Vives, Belgium Federal Holding Company, Wallonie Entreprendre, and Sambrinvest.

ATB Therapeutics specializes in developing therapeutic solutions intended to address critical needs in oncology and autoimmune diseases. Their core offerings include the atbody, a biologic format intended for targeted antibody therapies, particularly effective in treating hematological malignancies and autoimmune conditions. Additionally, the company offers Atbiofarm, a plant-based manufacturing technology that improves the production capabilities of their therapeutic products. These solutions target healthcare providers and institutions focused on oncology and immunology, with plans to expand their pipeline in solid tumors to meet unmet clinical needs across markets in Europe and North America.

ATB Therapeutics's revenue generation is primarily driven by partnerships and collaborations with healthcare organizations and pharmaceutical companies. Through strategic alliances, the company engages in business transactions involving the development and commercialization of its flagship products, including the ATB Ody and the ATB IOFarm technology.

The company plans to enhance its product offerings, focusing on new therapies aimed at solid tumors. Additionally, ATB Therapeutics aims to expand into new markets, specifically targeting regions in Europe and North America by the end of 2025, thereby leveraging its recent funding to facilitate this growth.

## Funding rounds

- Series A, Oct 29, 2024, $16M — EQT Life Sciences, Vives, Belgium Federal Holding Company, Sambrinvest, V-Bio Ventures, MRL Ventures Fund, Wallonie Entreprendre

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Vives (https://capitalatlas.ai/funds/vives) — Series A
- Belgium Federal Holding Company — Series A
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A
- Wallonie Entreprendre — Series A